Research programme: cyclo-oxygenase-2 inhibitors - Nobex
Alternative Names: COX-2 inhibitors research programme - Nobex; Cyclo-oxygenase-2 inhibitors research programme - Nobex; NNB 001; NNB 004; NNB 005; Research programme: COX-2 inhibitors - NobexLatest Information Update: 31 Mar 2004
Price :
$50 *
At a glance
- Originator Nobex Corporation
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 31 Mar 2004 Discontinued - Preclinical for Rheumatic disorders in USA (PO)
- 24 Jan 2001 New profile
- 24 Jan 2001 Nobex's COX-2 inhibitors programme is available for licensing (http://www.nobexcorp.com/)